These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 20140813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Influenza vaccine: globalization of public health stakes].
    Collin N, Briand S.
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N, de Radiguès X, World Health Organization H1N1 Vaccine Task Force.
    Vaccine; 2009 Aug 20; 27(38):5184-6. PubMed ID: 19563891
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
    Hasegawa H, Ichinohe T, Tamura S, Kurata T.
    Expert Rev Vaccines; 2007 Apr 20; 6(2):193-201. PubMed ID: 17408369
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
    George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L.
    Biotechnol Bioeng; 2010 Aug 15; 106(6):906-17. PubMed ID: 20589670
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of vaccines in chickens against highly pathogenic Hong Kong H5N1 avian influenza.
    Swayne DE, Beck JR, Perdue ML, Beard CW.
    Avian Dis; 2001 Aug 15; 45(2):355-65. PubMed ID: 11417815
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic?
    Pappaioanou M.
    Comp Immunol Microbiol Infect Dis; 2009 Jul 15; 32(4):287-300. PubMed ID: 19318178
    [Abstract] [Full Text] [Related]

  • 19. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS.
    Vaccine; 2008 Oct 23; 26(45):5736-40. PubMed ID: 18761387
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.